EGFR and non-small cell lung carcinoma: In addition, QTPlus‐AM21 could also sensitize A549 cells to erlotinib treatment in vitro (Figure 3C) with a combination index lower than 1 and DRI larger than 1, suggesting that QTPlus‐AM21 and erlotinib showed synergistic anticancer responses in vitro,[58] and QTPlus‐AM21 would be a promising anticancer agent alone or in combination with first‐line EGFR‐TKI‐based chemotherapies against NSCLC.[59]